𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

✍ Scribed by James A. Storlie; Jan C. Buckner; Gregory A. Wiseman; Patrick A. Burch; Lynn C. Hartmann; Ronald L. Richardson

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
503 KB
Volume
76
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A Phase II study of oral idarubicin as a
A Phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time
✍ Hans-Peter Schmid; Rudolf Maibach; Juerg Bernhard; Franz Hering; Silvia Hanselma πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 108 KB πŸ‘ 2 views

## Background: Treatment of hormone-refractory prostate carcinoma with chemotherapy is purely palliative, and reported response rates have been low. at the time this study was conducted, there was an urgent need for a trial using potentially efficacious drugs, with quality of life (ql), and serial

Clinical features of patients who presen
Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL : The β€œPSA negative” patients
✍ Alison J. Birtle; Alex Freeman; John R. W. Masters; Heather A. Payne; Stephen J. πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 108 KB πŸ‘ 1 views

## Background: Although < 1% of men present with prostate-specific antigen (psa)-negative prostate carcinoma, in that they have serum psa levels much lower than the tumor burden would suggest, such patients represent a management dilemma. to the authors' knowledge, little information exists in the